Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07446257 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

StatusRecruiting
PhaseEarly Phase 1
Started2026-09-01
View on ClinicalTrials.gov ↗

Amendment history

2026-09-01
Study Status, Contacts/Locations v3
Recruitment opened
Start dateestimated 2026-06-29→confirmed 2026-09-01
Study sitesdetails revised at 1 of 1 site
2026-07-02
Study Status v2
Primary completion moved earlier: 2030-09-01 → 2029-09-01
Completion moved earlier: 2031-08-01 → 2030-09-01
Primary completion pushed: 2030-05-01 → 2030-09-01
Completion pushed: 2031-05-01 → 2031-08-01
Start date2026-09-01→2026-06-29
2026-06-30
Study Status v1
Primary completion date2030-05-01→2030-09-01
Completion date2031-05-01→2031-08-01
Start date2026-05-01→2026-09-01
2026-02-25
Original filing
The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
Trial Details
NCT Number NCT07446257
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: Maia Biotechnology, National Cancer Institute (NCI)
Conditions Resectable Hepatocellular Carcinoma
Enrollment 60 participants
Start Date 2026-09-01
Primary Completion 2029-09-01 (estimated)
Study Completion 2030-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-03